Company intelligence / Profile preview

SynOx Therapeutics

Dublin, County Dublin, Irelandsynoxtherapeutics.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

SynOx is conducting a registrational Phase 3 clinical trial called TANGENT for emactuzumab in TGCT. The first patients were dosed in October 2024. Emactuzumab has shown promising efficacy in patients with TGCT and has a well-tolerated safety profile[4].

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

emactuzumab

Partnerships

Licensed emactuzumab from Roche (exclusive worldwide rights)[2]

Beyond the preview

Go deeper on SynOx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynOx Therapeutics.

Explore the full profile